Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 12/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 9/20 | 0.54 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.48 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 4/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18153334 | 0.84 | ABCG2 (0.63) | ABCG2ABCB1ABCC1 | |
| SCHEMBL2879724 | 0.84 | POLA1 (0.61) | ABCG2ABCB1ABCC1PIK3C3GAA | |
| SCHEMBL8298737 | 0.83 | ABCG2 (0.52) | ABCG2ABCB1ABCC1SMN1; SMN2POLA1 | |
| SCHEMBL19690974 | 0.81 | MAPT (0.52) | PTGESALOX5PPARGGAASMN1; SMN2 | |
| SCHEMBL18153342 | 0.81 | ABCG2 (0.51) | ABCG2ABCB1ABCC1KMT2A | |
| SCHEMBL23762975 | 0.78 | JAK2 (0.46) | PIK3C3 | |
| SCHEMBL29968899 | 0.78 | JAK2 (0.46) | PIK3C3 | |
| SCHEMBL18162580 | 0.78 | MAPT (0.45) | PTGESALOX5PPARGPPARAGAA | |
| SCHEMBL9870182 | 0.78 | MAPT (0.49) | GAASMN1; SMN2POLBMAPTMEN1 | |
| SCHEMBL4880624 | 0.78 | TXN (0.53) | ALOX5PPARGPPARAGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283472-B1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | UNIV INDIANA RES & TECH CORP (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10273228-B2 | Hepatitis B viral assembly effectors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273228-B2 | Hepatitis B viral assembly effectors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| EP-3283472-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | Indiana University Research&Technology Corporation (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168619-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168619-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | HAVCR2, MAVS, HCCS | ABCG2 4610/4885ABCB1 3136/4885ABCC1 4191/4885 |
| US-10273228-B2 | Hepatitis B viral assembly effectors | HAVCR2, MAVS, HCCS | ABCG2 4610/4885ABCB1 3136/4885ABCC1 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.